MBI begins clinical trials of FS069
Molecular Biosystems of San Diego has received Food and Drug Administrationapproval to begin phase-one human clinical studies of FS069, thecompany's second-generation ultrasound contrast agent for myocardialperfusion imaging. MBI is the developer of
Molecular Biosystems of San Diego has received Food and Drug Administrationapproval to begin phase-one human clinical studies of FS069, thecompany's second-generation ultrasound contrast agent for myocardialperfusion imaging. MBI is the developer of Albunex, the firstultrasound contrast agent approved for marketing in the U.S (SCAN8/31/94).
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
